The US House of Representatives has voted against the so-called "right to try" legislation, a proposal which would have permitted terminally ill patients in the USA to gain direct access to candidate therapies before they have been approved by the US Food and Drug Administration.
Under the proposals, any patient with a condition likely to cause death within months, or with "irreversible morbidity that is likely to lead to severely premature death” could request a medication under development, although drugmakers would not be obliged to provide it.
They would, however be afforded protection from any legal actions stemming from the use of such experimental drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze